Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | PPP3CA | Q08209 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872099 | 0.96 | FKBP1A (0.84) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL437462 | 0.95 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL17721321 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL439467 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL452381 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL13492308 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL25512 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL2390057 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL22409504 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A | |
| Ascomycin SCHEMBL14113233 | 0.95 | FKBP1A (1.00) | FKBP1AMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064575-A1 | CHEMO-ENZYMATIC APPROACH TO THE SYNTHESIS OF PIMECROLIMUS | AMRI ITALY S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064575-A1 | CHEMO-ENZYMATIC APPROACH TO THE SYNTHESIS OF PIMECROLIMUS | CYP51A1, PIM1, COASY | FKBP1A 1571/4885MEN1 2634/4885LMNA 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.